Ragistomig Biosimilar – Anti-Tumor necrosis factor receptor superfamily member 9; CD274 mAb – Research Grade

Description of Ragistomig Biosimilar - Anti-Tumor necrosis factor receptor superfamily member 9; CD274 mAb - Research Grade

Introduction

Ragistomig Biosimilar – Anti-Tumor necrosis factor receptor superfamily member 9, CD274 mAb – Research Grade is a novel biosimilar antibody that targets the CD274 protein, also known as programmed death-ligand 1 (PD-L1). This antibody has shown promising results in pre-clinical studies and is currently being evaluated for its potential use as a therapeutic agent in various types of cancer.

Structure of Ragistomig Biosimilar

Ragistomig Biosimilar is a monoclonal antibody, which means it is made up of identical immune cells that have been cloned from a single parent cell. It is a recombinant antibody, meaning it is produced in a laboratory using genetic engineering techniques. The antibody is designed to specifically target the CD274 protein, which is overexpressed in many types of cancer cells.

The antibody has a Y-shaped structure, with two identical heavy chains and two identical light chains. The heavy chains are made up of constant and variable regions, while the light chains have only variable regions. The variable regions are responsible for binding to the CD274 protein, while the constant regions provide stability and effector functions.

Mechanism of Action

The CD274 protein is a key immune checkpoint molecule that plays a crucial role in regulating the immune response.

Cancer cells often exploit this pathway to evade detection and destruction by the immune system. Ragistomig Biosimilar works by binding to the CD274 protein on the surface of cancer cells, thereby blocking its interaction with its receptor, programmed cell death protein 1 (PD-1). This prevents the cancer cells from suppressing the immune response and allows the immune system to recognize and destroy them.

In addition, the antibody also has an Fc region, which can activate immune cells such as natural killer cells and macrophages to directly kill cancer cells. This dual mechanism of action makes Ragistomig Biosimilar a potent anti- cancer agent.

Applications of Ragistomig Biosimilar

Ragistomig Biosimilar is currently being evaluated for its potential use in various types of cancer, including lung, breast, bladder, and head and neck cancers. It has shown promising results in pre-clinical studies, with significant inhibition of tumor growth and improved survival rates.

In addition to its use as a monotherapy, Ragistomig Biosimilar is also being studied in combination with other anti- cancer therapies, such as chemotherapy and other immunotherapies. This approach has shown synergistic effects, leading to enhanced anti-tumor activity and improved patient outcomes.

Research Grade Antibody

Ragistomig Biosimilar is produced under strict quality control measures to ensure its purity, potency, and consistency. It is manufactured using state-of-the-art technology and undergoes rigorous testing to meet the standards of a research-grade antibody. This makes it suitable for use in various research applications, such as in vitro and in vivo studies, as well as for diagnostic purposes.

Conclusion

Ragistomig Biosimilar – Anti-Tumor necrosis factor receptor superfamily member 9, CD274 mAb – Research Grade is a promising new biosimilar antibody that specifically targets the CD274 protein, a key immune checkpoint molecule in cancer. Its unique mechanism of action and potential for use in combination therapies make it a promising candidate for the treatment of various types of cancer. With its high quality and consistency, Ragistomig Biosimilar is also a valuable tool for research in the field of cancer immunotherapy.